Marina Pizzi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4721127/publications.pdf

Version: 2024-02-01

82 papers	3,554 citations	101543 36 h-index	149698 56 g-index
82 all docs	82 docs citations	82 times ranked	5001 citing authors

#	Article	IF	Citations
1	Review: Parkinson's disease: from synaptic loss to connectome dysfunction. Neuropathology and Applied Neurobiology, 2016, 42, 77-94.	3.2	163
2	A Bioinformatics Analysis of Memory Consolidation Reveals Involvement of the Transcription Factor c-Rel. Journal of Neuroscience, 2004, 24, 3933-3943.	3.6	157
3	Opposing Roles for NF-Î¹B/Rel Factors p65 and c-Rel in the Modulation of Neuron Survival Elicited by Glutamate and Interleukin-1Î². Journal of Biological Chemistry, 2002, 277, 20717-20723.	3.4	145
4	NF-Î¹B pathway: a target for preventing Î²-amyloid (AÎ²)-induced neuronal damage and AÎ²42 production. European Journal of Neuroscience, 2006, 23, 1711-1720.	2.6	131
5	Bim and Noxa Are Candidates to Mediate the Deleterious Effect of the NF-ÂB Subunit RelA in Cerebral Ischemia. Journal of Neuroscience, 2006, 26, 12896-12903.	3.6	119
6	Signal transduction and epigenetic mechanisms in the control of microglia activation during neuroinflammation. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 339-351.	3.8	118
7	Î±-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons. Journal of Cell Science, 2015, 128, 2231-2243.	2.0	99
8	Regulation of Nuclear Factor ÂB in the Hippocampus by Group I Metabotropic Glutamate Receptors. Journal of Neuroscience, 2006, 26, 4870-4879.	3.6	98
9	Attenuation of Excitatory Amino Acid Toxicity by Metabotropic Glutamate Receptor Agonists and Aniracetam in Primary Cultures of Cerebellar Granule Cells. Journal of Neurochemistry, 1993, 61, 683-689.	3.9	96
10	NFâ€Î¹B p50/RelA and câ€Relâ€containing dimers: opposite regulators of neuron vulnerability to ischaemia. Journal of Neurochemistry, 2009, 108, 475-485.	3.9	93
11	Chapter 24 NFâ€KappaB Dimers in the Regulation of Neuronal Survival. International Review of Neurobiology, 2009, 85, 351-362.	2.0	87
12	Leptin Increases Axonal Growth Cone Size in Developing Mouse Cortical Neurons by Convergent Signals Inactivating Glycogen Synthase Kinase-3Î². Journal of Biological Chemistry, 2006, 281, 12950-12958.	3.4	86
13	Prevention of neuron and oligodendrocyte degeneration by interleukin-6 (IL-6) and IL-6 receptor/IL-6 fusion protein in organotypic hippocampal slices. Molecular and Cellular Neurosciences, 2004, 25, 301-311.	2.2	84
14	Leptin Is Induced in the Ischemic Cerebral Cortex and Exerts Neuroprotection Through NF-Î¹B/c-Relâ€“Dependent Transcription. Stroke, 2009, 40, 610-617.	2.0	83
15	Targeted acetylation of NF-kappaB/RelA and histones by epigenetic drugs reduces post-ischemic brain injury in mice with an extended therapeutic window. Neurobiology of Disease, 2013, 49, 177-189.	4.4	83
16	Glutamatergic reinnervation through peripheral nerve graft dictates assembly of glutamatergic synapses at rat skeletal muscle. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 8752-8757.	7.1	76
17	NF-Î¹B in Innate Neuroprotection and Age-Related Neurodegenerative Diseases. Frontiers in Neurology, 2015, 6, 98.	2.4	73
18	Soluble Interleukin-6 (IL-6) Receptor/IL-6 Fusion Protein Enhances in Vitro Differentiation of Purified Rat Oligodendroglial Lineage Cells. Molecular and Cellular Neurosciences, 2002, 21, 602-615.	2.2	71

#	Article	IF	Citations
19	The Contribution ofÎ±-Synuclein Spreading to Parkinsonâ€™s Disease Synaptopathy. Neural Plasticity, 2017, 2017, 1-15.	2.2	70
20	Activation of Multiple Metabotropic Glutamate Receptor Subtypes Prevents NMDA-induced Excitotoxicity in Rat Hippocampal Slices. European Journal of Neuroscience, 1996, 8, 1516-1521.	2.6	68
21	Distinct roles of diverse nuclear factor-ÎºB complexes in neuropathological mechanisms. European Journal of Pharmacology, 2006, 545, 22-28.	3.5	67
22	Late-onset Parkinsonism in NFÂB/c-Rel-deficient mice. Brain, 2012, 135, 2750-2765.	7.6	66
23	Mitochondrial Dysfunction andÎ±-Synuclein Synaptic Pathology in Parkinsonâ€™s Disease: Whoâ€™s on First?. Parkinson's Disease, 2015, 2015, 1-10.	1.1	62
24	Expression of functional NR1/NR2B-type NMDA receptors in neuronally differentiated SK-N-SH human cell line. European Journal of Neuroscience, 2002, 16, 2342-2350.	2.6	56
25	Nuclear Factor-ÎºB Dysregulation and Î±-Synuclein Pathology: Critical Interplay in the Pathogenesis of Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2020, 12, 68.	3.4	56
26	The Î³-Secretase Modulator CHF5074 Restores Memory and Hippocampal Synaptic Plasticity in Plaque-Free Tg2576 Mice. Journal of Alzheimer's Disease, 2011, 24, 799-816.	2.6	53
27	Synapsin III deficiency hampers Î±-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinsonâ€™s disease. Acta Neuropathologica, 2018, 136, 621-639.	7.7	53
28	MicroRNAâ€‘34aâ€‘5p expression in the plasma and inÂits extracellular vesicle fractions in subjects with Parkinson's disease: An exploratory study. International Journal of Molecular Medicine, 2020, 47, 533-546.	4.0	49
29	Postâ€ischemic brain damage: NFâ€ÎºB dimer heterogeneity as a molecular determinant of neuron vulnerability. FEBS Journal, 2009, 276, 27-35.	4.7	48
30	Mitochondria and Î±-Synuclein: Friends or Foes in the Pathogenesis of Parkinsonâ€™s Disease?. Genes, 2017, 8, 377.	2.4	48
31	Various Ca2+ entry blockers prevent glutamate-induced neurotoxicity. European Journal of Pharmacology, 1991, 209, 169-173.	3.5	41
32	The Role of Mast Cells in Stroke. Cells, 2019, 8, 437.	4.1	41
33	1B/(âˆ’)IRE DMT1 Expression during Brain Ischemia Contributes to Cell Death Mediated by NF-ÎºB/RelA Acetylation at Lys310. PLoS ONE, 2012, 7, e38019.	2.5	40
34	Repeated administration of (âˆ’) sulpiride and SCH 23390 differentially up-regulate D-1 and D-2 dopamine receptor function in rat mesostriatal areas but not in cortical-limbic brain regions. European Journal of Pharmacology, 1987, 138, 45-51.	3.5	39
35	CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid. Neuroscience, 2015, 302, 112-120.	2.3	39
36	EGFR Amplified and Overexpressing Glioblastomas and Association With Better Response to Adjuvant Metronomic Temozolomide. Journal of the National Cancer Institute, 2015, 107, .	6.3	39

#	Article	IF	Citations
37	Synapsin III is a key component of Î±â€synuclein fibrils in Lewy bodies of PD brains. Brain Pathology, 2018, 28, 875-888.	4.1	37
38	Blockade of the Tumor Necrosis Factor-Related Apoptosis Inducing Ligand Death Receptor DR5 Prevents Î²-Amyloid Neurotoxicity. Neuropsychopharmacology, 2007, 32, 872-880.	5.4	36
39	Neuroprotective epi-drugs quench the inflammatory response and microglial/macrophage activation in a mouse model of permanent brain ischemia. Journal of Neuroinflammation, 2020, 17, 361.	7.2	36
40	Reversal of glutamate excitotoxicity by activation of PKC-associated metabotropic glutamate receptors in cerebellar granule cells relies on NR2C subunit expression. European Journal of Neuroscience, 1999, 11, 2489-2496.	2.6	34
41	Acetylation state of RelA modulated by epigenetic drugs prolongs survival and induces a neuroprotective effect on ALS murine model. Scientific Reports, 2018, 8, 12875.	3.3	30
42	Glutamatergic innervation of rat skeletal muscle by supraspinal neurons: a new paradigm in spinal cord injury repair. Current Opinion in Neurobiology, 2006, 16, 323-328.	4.2	27
43	The End Is the Beginning: Parkinsonâ€™s Disease in the Light of Brain Imaging. Frontiers in Aging Neuroscience, 2017, 9, 330.	3.4	26
44	Synergistic Association of Valproate and Resveratrol Reduces Brain Injury in Ischemic Stroke. International Journal of Molecular Sciences, 2018, 19, 172.	4.1	26
45	Plasma NfL, clinical subtypes and motor progression in Parkinson's disease. Parkinsonism and Related Disorders, 2021, 87, 41-47.	2.2	26
46	Neuroprotective effect of thyrotropin-releasing hormone against excitatory amino acid-induced cell death in hippocampal slices. European Journal of Pharmacology, 1999, 370, 133-137.	3.5	25
47	The Î³-Secretase Modulator CHF5074 Reduces the Accumulation of Native Hyperphosphorylated Tau in a Transgenic Mouse Model of Alzheimerâ€™s Disease. Journal of Molecular Neuroscience, 2011, 45, 22-31.	2.3	25
48	From Preclinical Stroke Models to Humans: Polyphenols in the Prevention and Treatment of Stroke. Nutrients, 2021, 13, 85.	4.1	25
49	PEA and luteolin synergistically reduce mast cell-mediated toxicity and elicit neuroprotection in cell-based models of brain ischemia. Brain Research, 2016, 1648, 409-417.	2.2	23
50	Inhibition of Glutamate-induced Neurotoxicity by a Tau Antisense Oligonucleotide in Primary Culture of Rat Cerebellar Granule Cells. European Journal of Neuroscience, 1995, 7, 1603-1613.	2.6	22
51	Alpha-Synuclein in the Regulation of Brain Endothelial and Perivascular Cells: Gaps and Future Perspectives. Frontiers in Immunology, 2021, 12, 611761.	4.8	22
52	An updated reappraisal of synapsins: structure, function and role in neurological and psychiatric disorders. Neuroscience and Biobehavioral Reviews, 2021, 130, 33-60.	6.1	22
53	NF-ÎºB/c-Rel deficiency causes Parkinsonâ€™s disease-like prodromal symptoms and progressive pathology in mice. Translational Neurodegeneration, 2019, 8, 16.	8.0	21
54	A Polyphenol-Enriched Supplement Exerts Potent Epigenetic-Protective Activity in a Cell-Based Model of Brain Ischemia. Nutrients, 2019, 11, 345.	4.1	21

#	Article	IF	Citations
55	A Tau antisense oligonucleotide decreases neurone sensitivity to excitotoxic injury. NeuroReport, 1993, 4, 823-826.	1.2	20
56	Possible new targets for GPCR modulation: allosteric interactions, plasma membrane domains, intercellular transfer and epigenetic mechanisms. Journal of Receptor and Signal Transduction Research, 2011, 31, 315-331.	2.5	20
57	Dopamine Transporter/Î±-Synuclein Complexes Are Altered in the Post Mortem Caudate Putamen of Parkinsonâ€™s Disease: An In Situ Proximity Ligation Assay Study. International Journal of Molecular Sciences, 2018, 19, 1611.	4.1	20
58	Pharmacological targeting of the Î²-amyloid precursor protein intracellular domain. Scientific Reports, 2014, 4, 4618.	3.3	19
59	Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate. Neurobiology of Disease, 2020, 138, 104789.	4.4	19
60	Glutamatergic Reinnervation and Assembly of Glutamatergic Synapses in Adult Rat Skeletal Muscle Occurs at Cholinergic Endplates. Journal of Neuropathology and Experimental Neurology, 2009, 68, 1103-1115.	1.7	17
61	Spinal cord mGlu1a receptorsPossible target for amyotrophic lateral sclerosis therapy. Pharmacology Biochemistry and Behavior, 2002, 73, 447-454.	2.9	16
62	Activation of Dopamine D2 Receptors Linked to Voltage-Sensitive Potassium Channels Reduces Forskolin-Induced Cyclic AMP Formation in Rat Pituitary Cells. Journal of Neurochemistry, 1992, 59, 1829-1835.	3.9	14
63	Differential expression of fetal and mature tau isoforms in primary cultures of rat cerebellar granule cells during differentiation in vitro. Molecular Brain Research, 1995, 34, 38-44.	2.3	14
64	NFâ€ÎºB and epigenetic mechanisms as integrative regulators of brain resilience to anoxic stress. Brain Research, 2012, 1476, 203-210.	2.2	14
65	Striatal adenylate cyclase-inhibiting dopamine D2 receptors are not affected by the aging process. Neuroscience Letters, 1987, 75, 38-42.	2.1	13
66	Mild Inflammatory Profile without Gliosis in the c-Rel Deficient Mouse Modeling a Late-Onset Parkinsonism. Frontiers in Aging Neuroscience, 2017, 9, 229.	3.4	12
67	Priming of cultured neurons with sabeluzole results in long-lasting inhibition of neurotoxin-induced tau expression and cell death. , 1997, 26, 95-103.		11
68	Synapsin III gene silencing redeems alpha-synuclein transgenic mice from Parkinson's disease-like phenotype. Molecular Therapy, 2022, 30, 1465-1483.	8.2	9
69	A Mechanism Additional to Cyclic AMP Accumulation for Vasoactive Intestinal Peptide-Induced Prolactin Release. Neuroendocrinology, 1990, 51, 481-486.	2.5	8
70	Beneficial and Sexually Dimorphic Response to Combined HDAC Inhibitor Valproate and AMPK/SIRT1 Pathway Activator Resveratrol in the Treatment of ALS Mice. International Journal of Molecular Sciences, 2022, 23, 1047.	4.1	8
71	Neuroprotective and Anti-Apoptotic Effects of CSP-1103 in Primary Cortical Neurons Exposed to Oxygen and Glucose Deprivation. International Journal of Molecular Sciences, 2017, 18, 184.	4.1	6
72	The good and bad of therapeutic strategies that directly target Î±â€synuclein. IUBMB Life, 2020, 72, 590-600.	3.4	6

#	Article	IF	Citations
73	Antisense strategy unravels tau proteins as molecular risk factors for glutamate-induced neurodegeneration. Cellular and Molecular Neurobiology, 1994, 14, 569-578.	3.3	5
74	Raman Probes for In Situ Molecular Analyses of Peripheral Nerve Myelination. ACS Chemical Neuroscience, 2020, 11, 2327-2339.	3.5	5
75	N-methyl-d-aspartate neurotoxicity in hippocampal slices: protection by aniracetam. European Journal of Pharmacology, 1995, 275, 311-314.	3.5	4
76	Tolerance to hypoactivity and sensitization to hyperactivity after chronic treatment with a presynaptic dose of lisuride in rats. European Journal of Pharmacology, 1992, 216, 81-86.	3.5	3
77	Glutamatergic Neurons Induce Expression of Functional Glutamatergic Synapses in Primary Myotubes. PLoS ONE, 2012, 7, e31451.	2.5	3
78	Differential up-regulation of D-1 and D-2 dopamine receptor function in mesostriatal areas but not in cortical-limbic brain regions of rats chronically treated with (?)sulpiride and SCH 23390. Drug Development Research, 1987, 11, 243-249.	2.9	2
79	Molecular mechanisms of glutamate-induced neurodegeneration. International Review of Psychiatry, 1995, 7, 339-348.	2.8	2
80	Age-Dependent Neuropsychiatric Symptoms in the NF-ÎºB/c-Rel Knockout Mouse Model of Parkinsonâ€™s Disease. Frontiers in Behavioral Neuroscience, 2022, 16, 831664.	2.0	2
81	NF-ÎºB in Neurons. , 2006, , 147-161.		1
82	Lack of vasoactive intestinal peptide-releasing property in prolactin cells from ovariectomized rats: contribution of post-transductional impairments. European Journal of Endocrinology, 1994, 130, 361-365.	3.7	0